An observational study in Advanced Prostate Cancer, sponsored by Ipsen. Completed at 35 sites in 7 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-14.
Sponsored by Ipsen · Observational
The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with advanced disease.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,397 are open to participants now.
This study's enrollment of 180 is close to the median of 200 across 1,179 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Ipsen is the lead sponsor of 282 studies on the registry; 16 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 19 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with previously diagnosed advanced prostate cancer, and who have participated in the Triptocare study and who have given written informed consent to participate in the study. They have therefore been treated with triptorelin (22.5 mg, intamuscular) as an ADT induction.
Exclusion Criteria:
Castration-resistant prostate cancer (CRPC)
Time frame: Over a 3-year period post-androgen deprivation therapy induction
Disease progression (DP) rate post-androgen deprivation therapy induction
Time frame: Over a 3-year period post-androgen deprivation therapy induction
Overall survival
Time frame: 3-years post-androgen deprivation therapy induction
Serum prostate specific antigen
Time frame: Over a 3-year period post-androgen deprivation therapy induction
Serum testosterone
Time frame: Over a 3-year period post-androgen deprivation therapy induction
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ipsen